Cervical lipomatosis in HIV-infected patients: a case-control study

HIV Med. 2007 Jan;8(1):17-21. doi: 10.1111/j.1468-1293.2007.00421.x.

Abstract

Objectives: The aim of the study was to analyse the prevalence of cervical lipomatosis (CL) in HIV-infected patients on highly active antiretroviral therapy (HAART) and the factors associated with its development.

Methods: This was a multicentre, observational, 1:1 case-control study. HIV-infected patients with CL (cases) and HIV-infected patients from the same cohort, controlled for age (+/-5 years), sex and body mass index (+/-2.5 kg/m(2)) (controls), were included in the study, and a multiple conditional logistic regression was performed to identify factors related to CL.

Results: CL was reported in 80 patients (1.8%) from a cohort of 4214 patients on HAART followed up in 10 Spanish hospitals. CL was associated with time of exposure to stavudine [for each 6-month increase, odds ratio (OR) 5.82, 95% confidence interval (CI) 5.70-5.94, P=0.0073] and lipoatrophy (OR 8.04, 95% CI 2.93-22.02, P=0.00001).

Conclusions: Although lipodystrophy is very frequent among HIV-infected patients on HAART, CL is an uncommon type of fat redistribution in this population, and in our cohort it was related to time of exposure to stavudine and lipoatrophy.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects
  • Antiretroviral Therapy, Highly Active
  • Case-Control Studies
  • Cohort Studies
  • Female
  • HIV Infections / epidemiology*
  • HIV-Associated Lipodystrophy Syndrome / epidemiology
  • Humans
  • Lamivudine / adverse effects
  • Lipomatosis / chemically induced
  • Lipomatosis / epidemiology*
  • Logistic Models
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • Spain / epidemiology
  • Spinal Diseases / chemically induced
  • Spinal Diseases / epidemiology*
  • Stavudine / adverse effects

Substances

  • Anti-HIV Agents
  • Lamivudine
  • Stavudine